Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer

by Andrew J. Browne, Marie L. Kubasch, Andy Göbel, Peyman Hadji, David Chen, Martina Rauner, Friedrich Stölzel, Lorenz C. Hofbauer, Tilman D. Rachner
Published 2017-08-01

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment

by Dennis Heinzen, Iris Divé, Nadja I. Lorenz, Anna-Luisa Luger, Joachim P. Steinbach, Michael W. Ronellenfitsch
Published 2019-09-01

Myeloid-Derived Suppressor Cells in Kidney Transplant Recipients and the Effect of Maintenance Immunotherapy

by María Iglesias-Escudero, David Sansegundo-Arribas, David Sansegundo-Arribas, Paloma Riquelme, David Merino-Fernández, Sandra Guiral-Foz, Sandra Guiral-Foz, Carmen Pérez, Rosalia Valero, Rosalia Valero, Juan Carlos Ruiz, Juan Carlos Ruiz, Emilio Rodrigo, Emilio Rodrigo, Patricia Lamadrid-Perojo, James A. Hutchinson, Jordi Ochando, Jordi Ochando, Marcos López-Hoyos, Marcos López-Hoyos
Published 2020-04-01

Metformin induces degradation of mTOR protein in breast cancer cells

by Mohamed Alalem, Alpana Ray, Bimal K. Ray
Published 2016-11-01

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

by Fabian Lang, Lydia Wunderle, Susanne Badura, Eberhard Schleyer, Monika Brüggemann, Hubert Serve, Susanne Schnittger, Nicola Gökbuget, Heike Pfeifer, Sebastian Wagner, Kevin Ashelford, Gesine Bug, Oliver G. Ottmann
Published 2020-09-01

Everolimus in Anaplastic Thyroid Cancer: A Case Series

by Ethan J. Harris, Glenn J. Hanna, Nicole Chau, Guilherme Rabinowits, Robert Haddad, Danielle N. Margalit, Jonathan Schoenfeld, Roy B. Tishler, Justine A. Barletta, Matthew Nehs, Pasi Janne, Julian Huang, Julian Huang, Phillip Groden, Alec Kacew, Jochen Lorch
Published 2019-02-01